TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06535399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986369
Description: Specified dose on specified days
Study: NCT04749108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy - modified FOLFIRINOX regimen
Description: An induction chemotherapy (6 cycles) combining irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2 followed by a 46-hour continuous infusion 2,400 mg/m2) will be delivered every 15 days (D1=D15).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction chemotherapy - modified FOLFIRINOX regimen
Description: An induction chemotherapy (6 cycles) combining irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2 followed by a 46-hour continuous infusion 2,400 mg/m2) will be delivered every 15 days (D1=D15).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early tumor response evaluation by MRI volumetry
Description: Two weeks after the CT completion, the tumor volume will be measured by MRI with specific software which automatically borders the tumor so as to determine the early tumor response. A centralized reassessment of all MRI exams will be systematically performed by two radiologists of the coordinator center.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early tumor response evaluation by MRI volumetry
Description: Two weeks after the CT completion, the tumor volume will be measured by MRI with specific software which automatically borders the tumor so as to determine the early tumor response. A centralized reassessment of all MRI exams will be systematically performed by two radiologists of the coordinator center.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiochemotherapy Cap 50
Description: RCT Cap 50 will combine radiotherapy at a dose of 50 Gy by either conventional 3D or Intensity-Modulated RadioTherapy (IMRT) (2 Gy per fraction, 5 fractions per week during 5 weeks / 44 Gy in mini pelvis, and boost 6 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of radiotherapy treatment (2 daily intake).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical proctectomy with total mesorectal excision
Description: The proctectomy can be performed by laparoscopic surgery or conventional laparotomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical proctectomy with total mesorectal excision
Description: The proctectomy can be performed by laparoscopic surgery or conventional laparotomy.
Study: NCT05962164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passive Heat Therapy
Description: The intervention will consist of 6 weeks of repeated (3x/week) 45-min lower-leg immersions.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Immersion
Description: The sham intervention will consist of 6 weeks of repeated (3x/week) 45-min lower-leg immersions.
Study: NCT06782139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enavogliflozin
Description: Patients who are enrolled in the study will undergo adenosine stress tests assessing coronary flow velocity reserve and body composition analysis on the day of registration. Within 2 weeks, cardiopulmonary exercise tests will be performed with exhalation gas analysis. After completing the baseline cardiopulmonary exercise capacity evaluation, patients will be assigned to either the enavogliflozin or placebo group and monitored for adverse effects within one month. Patients without significant adverse effects will continue the assigned treatment, and at 12 weeks, they will undergo re-evaluation of coronary flow velocity reserve, body composition analysis, and cardiopulmonary exercise capacity. Adverse events will be monitored from the date of enrollment through the final evaluation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients who are enrolled in the study will undergo adenosine stress tests assessing coronary flow velocity reserve and body composition analysis on the day of registration. Within 2 weeks, cardiopulmonary exercise tests will be performed with exhalation gas analysis. After completing the baseline cardiopulmonary exercise capacity evaluation, patients will be assigned to either the enavogliflozin or placebo group and monitored for adverse effects within one month. Patients without significant adverse effects will continue the assigned treatment, and at 12 weeks, they will undergo re-evaluation of coronary flow velocity reserve, body composition analysis, and cardiopulmonary exercise capacity. Adverse events will be monitored from the date of enrollment through the final evaluation.
Study: NCT06779903

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the psychoeducation intervention program booklet
Description: Psychoeducation Program was composed of nine basic topics (postpartum period and care, adaptation to the role of motherhood and mother-infant bonding, postpartum psychological changes, frequency, causes, symptoms of PPD, effects on mother, child and community health, diagnosis and treatment, preventive practices, social support and suggestions for coping, breast milk and breastfeeding, breast care and practices, nutrition and baby care).
Study: NCT05179408

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist
Description: 8-week waiting period prior to targeted telerehabilitation
Study: NCT06779903

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: routine care
Description: routine care
Study: NCT06782464

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment
Description: Treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Treatment
Study: NCT05930067

Intervention type: DEVICE
Group type: OTHER
Intervention: Pinnacle Gription Acetabular Cup
Description: Pinnacle Gription cup with Corail/ACTIS stem
Study: NCT06779838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Emotion Focused Therapy Intervention
Description: The EFT group intervention: Taming the Inner Critic: Emotion-Focused Group Therapy for Eating and Body Concerns. This group is a 10-12 week (number of participants=8-10 +2 sessions) closed therapy group for students seeking support regarding issues related to eating and/or body concerns. Working one-to-one and within the group, group members will be facilitated to recognise and explore some of the difficult emotions underlying and driving eating and/or body related issues. In particular, the group will focus on 'taming' the inner critic, that part of ourselves that criticises or chastises us for not being good enough. By identifying the critic in ourselves and by witnessing it in others, group members will be better positioned to figure out what they really need from themselves at times of difficulty, and thus better able to access self-compassion and self-assertion. There will be some psychoeducation, both around eating and emotions, but this will be largely in a handout format, with

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Treatment that would otherwise be offered by the university counselling service (one on one counselling, a group, or signposting to external support).
Study: NCT05930067

Intervention type: DEVICE
Group type: OTHER
Intervention: Pinnacle Dual Mobility
Description: Bi-Mentum AltrX liner
Study: NCT06017128

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sexual counseling based on the PLISSIT model
Description: In the initial follow-up, the experimental group will receive information about total hip replacement surgery and its impact on sexual life based on the PLISSIT model. An educational booklet containing information about total hip replacement surgery, the rehabilitation process, and post-operative sexual life will also be prepared and distributed. In the second follow-up (5-7 days after surgery), the experimental group will be provided with information about home care before discharge and returning to sexual life.
Study: NCT06782009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorie restriction
Description: Participants will be provided with a food menu guide for fifteen days with a 30% energy restriction (kcal) according to their usual diet, with a macronutrient distribution of 20-30% protein, 50-60% carbohydrates and 20-30% fat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent fasting 16/8
Description: Participants will be provided with a food menu guide for fifteen days with an energy intake according to the energy expenditure determined by indirect calorimetry with normal distribution of macronutrients. Intermittent fasting will be used with a time-restricted model of 16:8. For 16 hours, they will not be able to eat or drink calories. In the other 8 hours, they need to adhere to the energy-restricted diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Participants will be provided with a food menu guide for 15 days with an energy intake according to the energy expenditure determined by indirect calorimetry, with the following distribution of macronutrients: 20-25% protein, 5-10% carbohydrates, 70-80% fat.
Study: NCT06781788

Intervention type: OTHER
Group type: OTHER
Intervention: Making room for climate emotions in the classroom
Description: The Making room for climate emotions in the classroom program is designed to address emotions as students learn (formally or informally) about climate change. Each session features a drawing, photography, Lego sculpture, rock painting or collage/drawing workshop to address themes, explore emotions/feelings/experiences and initiate discussions on topics related to climate change.
Study: NCT06781333

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hMSC
Description: Participants will come in person to receive one intravenous infusion of approximately 25 million cells up to 20 minutes.
Study: NCT06782451

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery or biopsy
Description: A part of the tumor sample collected during the surgery or the biopsy performed as part of routine patient care will be used for the research.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: 38 mL of blood will be taken for the study.
Study: NCT05751668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monosialotetrahexosylganglioside
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary Studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary Studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: Ancillary Studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-life assessment
Description: Ancillary Studies

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given IV
Study: NCT05720884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture of a disposable, sterilized, stainless steel needle of 0.20 mm \* 30 mm size (Dongbang medical, Boryeong, Rep of Korea) will be used.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo acupuncture
Description: Acupuncture of a disposable, sterilized, stainless steel needle of 0.20 mm \* 30 mm size (Dongbang medical, Boryeong, Rep of Korea) will be used but in differene location.
Study: NCT06474117

Intervention type: OTHER
Intervention: Gait analysis coupled with ultrasound
Description: Measure the lengths of the Achilles tendon and gastrocnemius medialis muscle

Intervention type: OTHER
Intervention: Gait analysis coupled with ultrasound
Description: Measure the lengths of the Achilles tendon and gastrocnemius medialis muscle

Intervention type: OTHER
Intervention: Gait analysis coupled with ultrasound
Description: Measure the lengths of the Achilles tendon and gastrocnemius medialis muscle

Intervention type: OTHER
Intervention: Isokinetic dynamometer with simultaneous ultrasound
Description: Measure the force/length profile of the gastrocnemius medialis muscle

Intervention type: OTHER
Intervention: Isokinetic dynamometer with simultaneous ultrasound
Description: Measure the force/length profile of the gastrocnemius medialis muscle

Intervention type: OTHER
Intervention: Isokinetic dynamometer with simultaneous ultrasound
Description: Measure the force/length profile of the gastrocnemius medialis muscle
Study: NCT05175443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will be trained, by a physical therapist, to perform a set of four daily exercises requiring 1 sets of 2 minutes for each exercise totaling 8 minutes of targeted exercise per day for 8 weeks of the intervention. These exercises will be progressed or modified every 2-4 weeks to assure the participant is receiving maximal benefit for their exercise intervention.
Study: NCT05935280

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Room temperature
Description: Room temperature injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cold temperature
Description: Cold temperature injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cold temperature
Description: Cold temperature injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold temperature
Description: Cold temperature injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold temperature
Description: Cold temperature injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold temperature
Description: Cold temperature injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold temperature
Description: Cold temperature injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold temperature
Description: Cold temperature injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold temperature
Description: Cold temperature injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocain
Description: Unspecific sodium channel blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05105679
Description: Specific antagonist of the TRPM8 ion channel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05105679
Description: Specific antagonist of the TRPM8 ion channel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A967079
Description: Specific antagonist of the TRPA1 ion channel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A967079
Description: Specific antagonist of the TRPA1 ion channel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: Specific antagonist of the Nav1.7 sodium channel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: Specific antagonist of the Nav1.7 sodium channel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06305591
Description: Specific antagonist of the Nav1.8 sodium channel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06305591
Description: Specific antagonist of the Nav1.8 sodium channel
Study: NCT05174650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Infusion i.v. of atezolizumab on day 1 of a 3-week cycle, first infusion rate over 60 minutes, subsequent infusion rates 30 minutes if tolerated for a maximum of 20 cycles in total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib
Description: Oral intake of 300 mg derazantinib continuously on day 1 to day 21 of a 3-week cycle for a maximum of 20 cycles in total
Study: NCT06369324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain education
Description: It consisted of holding information sessions on each of the days that the subjects were scheduled for treatment. These sessions will be supported by supplementary material in the form of brochures, posters and videos which briefly explain interesting knowledge about spondyloarthropathies.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise supervised by external focus
Description: This therapeutic exercise involves proprioceptive training with external feedback to enhance exercise execution and promote optimal postural control, particularly for individuals with back pain. The method, based on research by Abdollahipour et al. and Chiviacowsky et al., focuses on automatic control, reducing the cognitive load during exercises and improving movement retention. The Motion Guidance Clinician Kit will be utilized, consisting of a panel and laser guide for precise cervical movement. Exercises progress in difficulty over 12 sessions, targeting cervical and lumbopelvic stabilization, flexion-extension, rotations, and lateral flexions. Sessions start with seated exercises and progress to standing, with increasing distance between laser targets to expand cervical range of motion. Thoracic and lumbar exercises involve 10 repetitions each. The entire program lasts around 20 minutes and follows Tidier recommendations for intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapy by means of electrical stimulation (electro-massage)
Description: This technique combines manual therapy (massage) with interferential current. Following a supervised therapeutic exercise program, this intervention targets the spine for 15 minutes. Using a Sonopuls 692® device, a bipolar current mode with specific frequencies is applied. The physiotherapist moistens sponges with warm water and administers the current through them while performing manual soft tissue therapy on the neck, shoulders, scapulae, thoracic, lumbar, and sacral areas. The intensity is adjusted to provide a strong but comfortable tingling sensation, without muscle twitching. The therapy sequence includes superficial stroking, deep gliding movements, trapezius kneading, muscle stretching, and deep rubbing on the thoracic and lumbar areas. The electro-massage protocol lasts 14 minutes.
Study: NCT05555030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iCura COVID-19 Antigen Rapid Home Test
Description: Candidate Ag self-test kit anterior nasal specimen collection and testing will be done under the supervision of qualified site personnel in person. Comparator NP samples shall be collected at least 15 minutes prior to Ag samples with at least 15 minutes between nasal collections including collections that may occur prior to study enrollment. Comparator samples will be collected first by qualified personnel at a study site or physician's office using an FDA authorized nasopharyngeal swab collection kit and SARS-CoV-2 molecular assay.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iCura COVID-19 Antigen Rapid Home Test
Description: Candidate Ag self-test kit anterior nasal specimen collection and testing will be done under the supervision of qualified site personnel in person. Comparator NP samples shall be collected at least 15 minutes prior to Ag samples with at least 15 minutes between nasal collections including collections that may occur prior to study enrollment. Comparator samples will be collected first by qualified personnel at a study site or physician's office using an FDA authorized nasopharyngeal swab collection kit and SARS-CoV-2 molecular assay.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: RT-PCR Test
Description: High sensitivity RT-PCR COVID-19 Test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: RT-PCR Test
Description: High sensitivity RT-PCR COVID-19 Test
Study: NCT06488326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mulberry leaf extract 6 mg capsule
Description: Take one capsule of the sample one time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mulberry leaf extract 12 mg capsule
Description: Take one capsule of the sample one time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mulberry leaf extract 18 mg capsule
Description: Take one capsule of the sample one time.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Take one capsule of the sample one time.
Study: NCT05956574

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrigenomix, personalized dietary plan
Description: Personalized dietary plan.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: Participate in an exercise program to work up to 300 min/week of moderate-intensity activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Participate in an exercise program to work up to 300 min/week of moderate-intensity activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral counseling
Description: Review behavioral counseling videos and participate in worksheets to assist with behavioral change.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral counseling
Description: Review behavioral counseling videos and participate in worksheets to assist with behavioral change.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dietary plan
Description: Receive a standard dietary plan
Study: NCT06175507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexon
Description: Naltrexone 50mg orally once daily will give for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: Baclofen 10mg orally thrice daily will give for 12 weeks